The Line

Matt Gurney and Jen Gerson
  • 0.0 (0)
  • News Commentary
  • Updated weekly

The Line is a Canadian magazine dedicated to covering local, national and international politics, news, current events and occasionally some obscure stories.  Hosted by Matt Gurney and Jen Gerson.

  1. 11 hr ago

    Over the pump

    In this episode of On The Line, host Jen Gerson is joined by Andrew Leach, noted energy and environmental economist and professor of economics and law at the University of Alberta, for a conversation about Canadian energy policy at a pivotal moment. This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network bringing cutting edge cancer immunotherapy research from Canadian labs to patients in clinical trials –– all in Canada. A drug that can treat your cancer is being tested in a Canadian clinical trial, but can you access it? Depends — where do you live? Clinical trials taking place in Canada usually open sites in major centers with research hospitals. Smaller hospitals face many challenges including having enough know-how to deliver experimental therapies, and administrative, legal, and regulatory responsibilities that come with a trial. There are also data and interoperability issues at hospitals that don't routinely participate in research. So if you don’t live in a major centre, participating in the trial requires you to relocate there for the duration of treatment –– the cost of the treatment is covered, but the cost of being in the city where it happens is your responsibility. Patient advocacy groups might be able to help with some of those expenses, but this obviously can be a barrier for a lot of Canadians.  A therapy might only become available to everyone across Canada if a trial is successful and the drug is approved –– but not necessarily, and maybe not anytime soon. More on that next time. Visit BioCanRx.com to learn more. Recorded on July 2, 2026, just ahead of two major pipeline announcements, the discussion doesn’t cover the specifics of the federal government’s decision to retrace the TMX route or the proposed Canadian Shield pipeline between Alberta and Sarnia. Instead, Gerson and Leach focus on the broader forces shaping Canada’s energy future. They discuss Prime Minister Mark Carney’s latest Forward Guidance video, the influence of the United States on Canadian energy policy and markets, the promise and limitations of carbon capture and storage, and the political significance of the new Memorandum of Understanding between Alberta and Ottawa. Throughout the conversation, Leach offers his perspective on what has changed — and what hasn’t — in the relationship between governments, industry, and the public. This episode is also brought to you by the Forest Products Association of Canada. Canada’s forest products sector is not asking Ottawa to start over. The federal government has heard the advice. It has recognized the challenges. And it has put a plan on the table. Now the test is action. That means clearing made-in-Canada barriers: regulatory duplication, transportation bottlenecks, and uncertainty around predictable access to manage our forests. It means working with provinces to protect communities from wildfire risk and giving companies the confidence to invest here at home. Nearly 200,000 Canadians working in this sector are looking for results. The playbook is written. Now Ottawa needs to deliver. Learn more at fpac.ca. The episode also asks a larger question: after decades of political conflict over pipelines, is Canada finally entering a new era? Could this be the beginning of a more grounded conversation about the country’s oil and gas sector, one that focuses less on symbolic battles and more on practical questions of economics, infrastructure, and national interest? This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. If you enjoyed the episode, be sure to share it, and as always, like and subscribe to us on your podcast or video app of choice. Be sure to check out our main page at ReadTheLine.ca. #OnTheLine #AndrewLeach #Energy #Pipelines #TMX #OilAndGas #MarkCarney #Alberta #CanadaPolitics #JenGerson

    58 min

  2. 4 days ago

    Carney gets a pipeline deal. Now let's build the damn thing

    In the latest episode of The Line Podcast, recorded on July 3rd, 2026, Matt Gurney and Jen Gerson begin with the biggest political news of the week: a pipeline deal. Prime Minister Mark Carney has struck agreements with both Alberta and British Columbia to move another pipeline project forward. Your hosts discuss the proposed route, which closely follows the existing Trans Mountain corridor, the political wheeling and dealing that made the agreement possible, and what it could mean for Alberta’s upcoming referendum. Matt also can’t help asking an obvious question: since this was always the logical outcome, why did it take so long? Was there a genuine engineering obstacle behind the scenes, or are Canadian governments simply incapable of moving quickly? This episode is brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca. Next, they turn to another round of comments from U.S. Ambassador Pete Hoekstra. After a brief discussion of CUSMA, the conversation shifts to Hoekstra’s remarks about the Gordie Howe International Bridge. Your hosts aren’t especially worried. In fact, they think they have the perfect strategy: troll the White House until it becomes so embarrassed that it can’t wait to open the bridge just to make the pain stop. Their suggestions include live episodes of The View from the bridge deck, Bruce Springsteen concerts, and, naturally, renaming it the Barack Hussein Obama Nobel Peace Prize Bridge of Friendship. This episode is also brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network focused on cutting-edge immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada.Clinical trials are the way new drugs, including immunotherapies, are tested in patients around the world. Health Canada, our national regulator, reviews and approves all Clinical Trial Applications, or CTAs, returning a decision within 30 days –– a similar turnaround time as the US FDA and other major jurisdictions. To submit a complete CTA, applicants need to provide hundreds –– sometimes thousands –– of pages of data showing that a drug has a compelling chance of providing benefit, that it can be manufactured consistently, and that it’s safe to administer to trial participants. This is especially hard for Canadian researchers because scientific studies that generate the necessary data aren't supported by many federal grants, which usually prioritize originality over real world impact. BioCanRx helps Canadian researchers succeed in the CTA process, and so far they’ve gotten 16 therapies to trial. To learn more, visit BioCanRx.com. Finally, Matt attempts to diagnose what has gone wrong with Canada’s civic culture and even ventures a possible cure. Toronto, he argues, needs its own version of the Calgary Stampede, and Canada more broadly needs something capable of genuinely uniting the country. The trouble is that neither host can think of an obvious candidate. They conclude that Canada — and Toronto in particular — has become too self-conscious and too embarrassed by its own past to celebrate it with much enthusiasm. All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca. #TheLinePodcast #MarkCarney #PipelinePolitics #CanadianPolitics #CanadaUSRelations #CUSMA #GordieHoweBridge #AlbertaPolitics #PoliticalAnalysis #CurrentAffairs

    1hr 19min

  3. 30 Jun

    Frontlines of Canadian Emergency Care

    In this episode of On The Line, host Matt Gurney sits down with Dr. Brian Goldman, veteran emergency physician at Mount Sinai Hospital in Toronto and author of The Casino Shift: Stories from an ER on the Edge, for a candid conversation about the state of emergency medicine in Canada. (You can find it on Indigo's website, or, if you prefer, on Amazon.) This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network bringing cutting edge cancer immunotherapy research from Canadian labs to patients in clinical trials –– all in Canada. Clinical trials are the way new drugs, including immunotherapies, are tested in patients around the world. It’s up to the developer of the drug to decide whether they want to trial it in Canada –– and many do. Health Canada, our national regulator, reviews and approves all Clinical Trial Applications, or CTAs, returning a decision within 30 days –– a similar turnaround time as the U.S. FDA and other major jurisdictions. If they approve, and if the trial receives research ethics approval, it can start enrolling Canadian patients. To submit a complete CTA, applicants must provide hundreds –– sometimes thousands –– of pages of data showing that a drug has a compelling chance of providing benefit, that it can be manufactured consistently, and that it’s safe to administer to trial participants. This is especially hard for Canadian researchers because scientific studies that generate the necessary data aren't supported by many federal grants, which usually prioritize originality over real-world impact. BioCanRx helps Canadian researchers succeed in the CTA process, and so far they’ve gotten 16 therapies to trial. But once a trial starts, how can Canadians learn about it, and where can they access it? That question and more next time. Visit BioCanRx.com to learn more. Drawing on decades in one of the country’s busiest emergency departments, Goldman explains why today’s ERs are under extraordinary strain, and why the problems extend far beyond long wait times. They discuss the pressures facing doctors, nurses, and patients alike, the growing mismatch between demand and capacity, and why the old problem of hallway medicine is increasingly giving way to something even worse: chair medicine, with patients waiting for hours in chairs because there simply isn’t anywhere else to put them. The conversation also explores the human side of emergency medicine. Goldman reflects on the emotional and psychological toll of working in an overwhelmed system, the stories that inspired The Casino Shift, and what keeps health-care workers coming back despite the mounting pressures. This episode is also brought to you by the Forest Products Association of Canada. A stronger forest industry can help build Canada strong. We need more homes, faster and more affordably, and Canadian wood can be part of the solution. Light-frame construction, mass timber, modular systems, and other modern building methods can support housing, lower embodied carbon, and strengthen domestic supply chains. The same opportunity exists in schools, health facilities, community buildings, and public infrastructure. When Canada builds, Canadian materials and Canadian workers must be part of the plan. Learn more at fpac.ca. Finally, Matt and Goldman tackle one of the most contentious questions in Canadian health care. Goldman argues that it’s time for a calm, respectful, and evidence-based discussion about whether private options should play a larger role within Canada’s publicly funded system. Rather than treating the issue as ideological warfare, he makes the case for focusing on what actually improves patient care, and how other jurisdictions are approaching this problem. It’s a frank discussion about the realities facing Canada’s healthcare system, the people trying to hold it together, and the difficult choices that may lie ahead. This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. If you enjoyed the episode, be sure to share it, and as always, like and subscribe to us on your podcast or video app of choice, and check out our main page at ReadTheLine.ca. #OnTheLine #BrianGoldman #Healthcare #EmergencyMedicine #CanadianHealthcare #MountSinai #TheCasinoShift #PublicHealth #CanadaPolitics #MattGurney

    1hr 1min

  4. 26 Jun

    Carney makes the easy call to fix our most symbolic national embarrassment

    In today’s episode of The Line Podcast, recorded on June 26th, 2026, Matt Gurney and Jen Gerson begin with a rare moment of joy. After decades of delay and political paralysis, there is finally a plan to deal with 24 Sussex Drive. Your hosts don’t love every aspect of it, but they’re so relieved that someone has finally decided to do something that they’re prepared to celebrate. Now comes the hard part: not finding a way to mess it up. This episode of The Line Podcast is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. From there, they turn to the tragic shooting in Montreal that claimed the life of another police officer. Beyond the immediate heartbreak, your hosts focus on two broader issues. First, they argue that the media should have published the shooter’s manifesto. By choosing not to do so, they contend, some early reporting ended up being incomplete or inaccurate. Second, they discuss the rush by commentators across the political spectrum to comb through the manifesto looking for evidence that the attacker perfectly represented their opponents — or, failing that, had nothing whatsoever to do with their own side. Matt and Jen argue that modern terrorism is often ideologically incoherent, and that treating every attack as an opportunity for partisan point-scoring will only make it harder to understand and prevent future violence. This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca. Finally, Jen makes a wardrobe change that only video viewers will fully appreciate before walking Matt through the increasingly strange politics of the Calgary Stampede. What was once simply Alberta’s biggest annual celebration is now becoming another front in an ongoing proxy war between competing factions within the broader conservative movement. This episode is also brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network, which helps bring cutting edge cancer immunotherapy research from Canadian scientists from labs to patients in clinical trials –– all in Canada. Cancer is very good at evading your immune system. But in some tumors, researchers find cancer-killing immune cells called tumour infiltrating lymphocytes, or TILs. They get inside the tumour and start fighting — but they’re outnumbered and ill equipped. Researchers in Canada and around the world are studying techniques to extract them from a tumour and multiply them in a lab. Once they number in the millions, they’re injected back into the tumour to do more damage. Research into this line of attack against cancer is ongoing. There are plenty of unanswered questions, and we're working hard to answer them. Learn more about this and other critical work at BioCanRx.com. All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca, and as ever, like and subscribe. #TheLinePodcast #CanadianPolitics #24Sussex #Montreal #CalgaryStampede #AlbertaPolitics #PoliticalAnalysis #CanadianMedia #LawEnforcement  #CurrentAffairs

    1hr 12min

  5. 23 Jun

    Carney condo bailout? Not quite

    In today’s episode of On The Line, host Matt Gurney is joined by two guests for conversations about housing, politics, and why governments sometimes struggle to explain themselves. This episode is brought to you by BioCanRx. When your immune system recognizes that cancer is a problem, but can’t kill it, can science help? This summer we’re partnering with BioCanRx, a federally-funded Canadian not-for-profit research network, to learn about cutting edge cancer immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada. One of the reasons cancers are so destructive is because they find ways to evade your immune system. But in some tumours, researchers find cancer-killing immune cells called "tumour infiltrating lymphocytes," or TILs. These are like infantry grunts choosing to stand their ground during the final fight in a superhero movie. They get inside the tumour and start fighting – –but they’re outnumbered and ill equipped. They need reinforcements. Researchers in Canada and around the world are studying techniques to extract them from a tumour and multiply them in a lab environment. Once they number in the millions, they're sent back into the fight. Research into this line of attack against cancer is ongoing, and there are plenty of questions — we'll be covering more of them over the course of the summer. Go to BioCanRx.com to learn more about these new ways of fighting cancer. First up is Mike Moffatt of the Missing Middle Initiative and co-host of the Missing Middle Podcast. He joins Matt to discuss the much-debated “condo bailout” and why, despite the label, it isn’t actually a condo bailout at all. Moffatt argues that the government has done itself no favours by communicating the policy so poorly, and walks listeners through what the plan is — and what it isn’t. The conversation then broadens into a look at the state of housing in Canada more generally. There are some signs of progress, but the underlying challenges remain enormous, and Moffatt explains why solving them will require much more than a handful of headline-grabbing announcements. This episode is also brought to you by the Forest Products Association of Canada. A stronger forest industry depends on getting goods to market. Forest products move by truck, rail, and ship, and reliability matters. When costs rise or shipments stall, mills, workers, customers, and communities all feel the impact. Stronger trade corridors, better rail performance, labour stability, and reliable transportation should be treated as core parts of Canada’s productivity agenda. For a sector rooted in communities and connected to global markets, transportation is transformation. Learn more at FPAC.ca. Then Matt is joined by Andrew MacDougall of Trafalgar Strategy for a look across the Atlantic at the increasingly turbulent state of British politics. They discuss the struggles of now-outgoing Prime Minister Keir Starmer, the rise of Andy Burnham as a potential future national leader, and why so many observers now see the United Kingdom as becoming increasingly difficult to govern. MacDougall argues that the country’s problems run deeper than any one politician or party, and offers his own diagnosis of what has gone wrong. It’s a pair of conversations about institutions under strain, political communication, and the challenge of governing in an era when public patience is increasingly in short supply. This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. Check out our main page at ReadTheLine.ca, and as always, like and subscribe. #OnTheLine #Housing #MikeMoffatt #MissingMiddle #CanadaHousing #KeirStarmer #AndyBurnham #UKPolitics #AndrewMacDougall #MattGurney

    1hr 18min

  6. 19 Jun

    Why does America hate us, we're poor

    In the latest episode of The Line Podcast, recorded on June 19th, 2026, Matt Gurney and Jen Gerson begin with a foreign affairs roundup. Prime Minister Mark Carney heads to Ireland and France to strengthen ties with Europe while also trying to maintain a workable relationship with Donald Trump. Meanwhile, U.S. Defense Secretary Pete Hegseth visits NATO and delivers some pointed criticism of allies that, while not directed at Canada by name, certainly sounds familiar. Your hosts also discuss the aftermath of America’s confrontation with Iran. Matt argues that the United States has, in practical terms, suffered a defeat — an embarrassing outcome for Trump, but perhaps a useful lesson for the rest of us about the limits of military power. This episode is brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca. Next, they take a quick tour through the provinces. Matt is increasingly worried that Doug Ford could inadvertently throw Canada-U.S. negotiations into chaos, and explains why. Jen provides an update from Alberta, where the political situation remains bizarre. By the end of the segment, both hosts arrive at a grim conclusion: the incentives facing almost every major political actor now reward escalation, confrontation, and nastiness. That rarely ends well. This episode of The Line Podcast is also brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network helping Canadian researchers bring treatments from labs to patients in clinical trials –– all in Canada. Every day, your immune system finds and destroys different types of threats –– both external invaders like viruses, and internal dangers like pre-cancerous cells in your own body. But cancer can sometimes evade detection. Researchers are working to identify flags found on cancer cells, called antigens. By training your immune system to recognize these antigens, immunotherapy can help your immune system destroy cancer.  In addition to funding clinical trials, BioCanRx supports research teams who identify these cancer antigens, and find new ways to target them. Many challenges remain — and we’re working on solving them. You’ll hear more over the summer. For now, go to BioCanRx.com to learn more. Finally, Jen disappears down one of her trademark rabbit holes and emerges with a sweeping explanation of how she came to fully appreciate the sheer economic power of the United States. Somehow, this journey involves gas pumps, brisket, beef jerky, the Soviet Union, and the defeat of Imperial Japan in 1945. Your hosts find themselves reflecting on what American economic dominance really means, why it has proven so durable, and what lessons Canada should draw from it as we navigate an increasingly uncertain world. All that and more in the latest episode of The Line Podcast. Check us out on our main page, ReadTheLine.ca. #TheLinePodcast #MarkCarney #DonaldTrump #CanadaUSRelations #AlbertaPolitics #DougFord #CanadianPolitics #Geopolitics #NATO #CurrentAffairs

    1hr 21min

  7. 16 Jun

    America — but Bigger

    In today’s On The Line, host Jen Gerson speaks with Mark Kawar, an amateur historian and journalist whose book America But Bigger explores a surprisingly persistent feature of American history: attempts to expand the United States beyond its current borders. This episode of On The Line is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network helping Canadian researchers bring treatments from labs to patients in clinical trials –– all in Canada.  Cancer can hide from your immune system. So how can we target it? Every day, your immune system finds and destroys different types of threats –– both external invaders like viruses, and internal dangers like pre-cancerous cells in your own body. But no system is perfect — sometimes something evades detection. Researchers are working to identify flags found on cancer cells, called antigens. By training your immune system to recognize these antigens as signals for destruction, some forms of immunotherapy equip your immune system to respond to cancer’s asymmetrical threat.    In addition to funding clinical trials, BioCanRx supports research teams who identify cancer antigens, and find new ways to target them with immunotherapies. There’s still a lot to figure out. Can we train the immune system to hit these antigens before cancer takes root? Why do some cancers still manage to evade therapies designed to find their antigens? Many other questions remain — and we’re working on answering them. You’ll hear more over the summer. For now, go to BioCanRx.com to learn more. Kawar walks Gerson through the long history of American expansionist ambitions, from schemes that never got off the ground to serious efforts that came much closer to success than many people realize. Along the way, he notes that not every annexation proposal was unwelcome to the people being annexed, and that the historical record is often more complicated than simple stories of American aggression. This episode is also brought to you by the Forest Products Association of Canada. A stronger forest industry means investing in the mills and facilities that anchor communities across Canada. Companies are ready to modernize with cleaner equipment, better energy efficiency, advanced wood products, biomaterials, and smarter use of every part of the tree. These are productive, lower-emission, export-oriented investments. But good projects need a workable business case. Our economy needs practical tools to unlock private capital and keep investment here. Learn more at fpac.ca. More importantly, Kawar examines why so many of these projects ultimately failed. The United States has often possessed enormous economic, military, and political power, but translating that power into lasting territorial expansion has proven more difficult than many Americans imagined. Again and again, resistance, geography, politics, and simple practicality imposed limits on what even the world’s most powerful country could accomplish. The result is a fascinating conversation about ambition, empire, national identity, and the often-overlooked constraints on American power. It’s also a discussion that may hold some lessons for Canadians, should they ever find themselves wondering about the limits of U.S. influence. For whatever reason. This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. Visit our main page at ReadTheLine.ca. Be sure to like and subscribe. We’ll be back on Friday with another episode of The Line Podcast. #Canada #Politics #UnitedStates #Greenland #annexation #51 #51State #OnTheLine

    48 min

  8. 12 Jun

    Canada and America, a (gross) love story

    In the latest episode of The Line Podcast, recorded on June 12th, 2026, Matt Gurney and Jen Gerson begin with an update from Alberta. Jen reviews Pierre Poilievre’s recent speech on why Alberta belongs in Canada. She liked it, with some caveats. Matt was somewhat more encouraged. He also has a few sharp words for Liberals who seem determined to police the boundaries of acceptable federalism. His view is simple: if people are defending Canada, let them defend Canada. Not every argument for national unity needs to come packaged with Liberal talking points. From Toronto, Matt also reflects on a genuine tragedy this week — a police officer killed in the line of duty while confronting a problem that had been allowed to fester for far too long. It’s difficult to discuss without emotion. In his view, it never should have ended this way. But, alas, it was always going to: even if the exact tragedy was unforeseen, a tragedy was inevitable.  This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. The hosts then take a very different turn. In what may be the strangest segment of the year, Jen reimagines 250 years of Canada-U.S. relations as a raunchy romantic comedy full of love, betrayal, heartbreak, and, yes, sex. Video viewers can watch Matt become increasingly horrified as the bit unfolds — not because he disagrees with the analysis, but because he finds himself unable to refute it. This episode is also brought to you by BioCanRx, a federally funded, not-for-profit Canadian research network that specializes in bringing Canadian cancer immunotherapy research from the lab all the way to patients in clinical trials in Canada. Immunotherapy is about assisting your immune system in identifying unhealthy cells –– especially cancer –– that have found a way to evade detection. One way researchers are doing this is through something called CAR T. They draw your blood, isolate one type of your immune cells –– T-Cells –– and use a virus to inject genetic instructions that cause them to grow new receptors designed specifically to find and destroy your particular cancer. In one of the 16 trials BioCanRx funds based on Canadian technology, CLIC-01, the median number of months remaining for patients with late-stage leukemia and lymphoma tripled. Some have been cancer free for years. You’ll hear more over the summer. For now, go to BioCanRx.com to learn more After that, the hosts wrap up with a discussion about children and social media. Both agree that kids probably shouldn’t be spending their lives online. Their concern is that any attempt by the government to solve that problem could easily create several new ones. If recent experience is any guide, they aren’t especially confident Ottawa can regulate this area without making a mess of it. All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca, and, as ever, like and subscribe.  #TheLinePodcast #PierrePoilievre #AlbertaPolitics #CanadianPolitics #CanadaUSRelations #SocialMedia #Parenting #NationalUnity #PoliticalPodcast #CurrentAffairs

    1hr 47min
See All (211)

Trailer

About

The Line is a Canadian magazine dedicated to covering local, national and international politics, news, current events and occasionally some obscure stories.  Hosted by Matt Gurney and Jen Gerson.

Information

  • Creator
    Matt Gurney and Jen Gerson
  • Years Active
    2023 - 2026
  • Episodes
    211
  • Rating
    Explicit
  • Copyright
    © 2026 The Line
  • Show Website
    The Line

You Might Also Like